This narrative review discusses the mechanisms of key GLP-1 RAs, including exenatide, liraglutide, and semaglutide, and examines various clinical trial data supporting their effectiveness in achieving substantial weight reduction in individuals with and without diabetes. Here, GCG is linked to diabetes mellitus.